116077 ⎘
Transferases transferring phosphorus-containing groups (2.7); Protein-serine/threonine kinases (2.7.11) Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
PLANTS GENETICALLY ENGINEERED FOR INCREASED WATER USE EFFICIENCY AND CARBON INTAKE AND METHODS FOR MAKING AND USING THEM
#2ENGINEERING SUICIDE GENE APPROACHES TO IMPROVE CHEMOTHERAPEUTIC RESPONSE IN CANCER
#3METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA
#4JNK3 INHIBITORY PEPTIDES
#5USE OF PHOSPHORYLATED TAU AND P38GAMMA TO TREAT A NEUROLOGICAL CONDITION
#6Method for Predicting Therapeutic Response to Serine-Theronine Kinase Braf Inhibitor Drugs
#7Methods and compounds for the treatment or prevention of severe influenza
#8METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY
#9REPROSOMES, AS EXOSOMES CAPABLE OF INDUCING REPROGRAMMING OF CELLS AND PREPARATION METHOD THEREOF
#10USE OF PHOSPHORYLATED TAU AND P38GAMMA TO TREAT A NEUROLOGICAL CONDITION
#11Methods of Treating Angiogenesis-Related Disorders Using JNK3 Inhibitors
#12Methods and compounds for the treatment or prevention of severe influenza
#13Medicament for liver regeneration and for treatment of liver failure
#14MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE
#15Methods for molecular classification of fatty liver by high-throughput protein post-translational modifications
#16METHOD OF TREATING CANCER
#17METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA
#18Compositions and methods of increasing longevity or treating cellular stress
#19Method for treatment of metastatic and refractory cancers and tumors with an inducer that overcomes inhibition of T cell proliferation
#20Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
#21ERK1 and ERK2 mutations that confer resistance to MAPK pathway inhibitors
#22ERK-derived peptides and uses thereof
#23Selective inhibitors of c-Fos and their antiproliferative properties
#24Compositions and methods for controlled delivery of inhibitory ribonucleic acids
#25Medicament for liver regeneration and for treatment of liver failure
#26Therapeutics with conformationally restricted monomers
#27Pain treatment using ERK2 inhibitors
#28Medicament for liver regeneration and for treatment of liver failure
#29MEK ligands and polynucleotides encoding MEK ligands
#30Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy
#31COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRABBE AND OTHER NEURODEGENERATIVE DISEASES
#32Pain treatment using ERK2 inhibitors
#33MEK ligands and polynucleotides encoding MEK ligands
#34JNK3 as a target for the treatment of angiogenesis-related diseases
#35MODIFIED POLYNUCLEOTIDES FOR USE IN RNA INTERFERENCE
#36Modulation of Immunostimulatory Properties of Short Interfering Ribonucleic Acid (Sirna) by Nucleotide Modification
#37Modified short interfering RNA
#38Modified polynucleotides for reducing off-target effects in RNA interference
#39Method For Preventing or Treating Pain in a Mammal
#40Antisense modulation of p38 mitogen activated protein kinase expression
#41MODIFIED POLYNUCLEOTIDES FOR USE IN RNA INTERFERENCE
#42Modified polynucleotides for use in rna interference
#43Modified polynucleotides for reducing off-target effects in RNA interference
#44Map kinase integrin-binding domain
#45Conjugated oligomeric compounds and their use in gene modulation